Forge Boosts Efficiency And Compliance During External Collaboration

Rare diseases affect an estimated 30 million people in the U.S., yet 95% lack FDA-approved treatments. Accelerating access to therapies requires efficient collaboration between CDMOs and their clients. Forge Biologics tackled this challenge by implementing a unified quality management platform to streamline document control, approvals, and quality event oversight. By replacing fragmented processes with secure, collaborative workflows, Forge reduced turnaround times for batch record reviews and approvals, enabling faster clinical trial readiness. The approach not only improves compliance but also enhances visibility for clients, ensuring critical quality decisions happen in real time.

Learn how connected systems and collaborative authoring can transform external partnerships and speed the path from development to GMP manufacturing.